Clinical Trial Update: Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating neoadjuvant tislelizumab in combination with chemotherapy for resectable locally-advanced head and neck squamous cell carcin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Xiang Lu | Conditions: Head and Neck Squamous Cell Carcinomas, Resectable Head and Neck Squamous-cell Carcinoma | Phase 2 | Status: UNKNOWN